

## Effets indésirables associés au traitement par bisphosphonates

Forum Med Suisse. 2012;12(16):323–6.

## Nebenwirkungen einer Bisphosphonat-Therapie

Schweiz Med Forum. 2012;12(16):323–6.

### Références / Literatur

- 1 Rizzoli R, Bruyere O, Cannata-Andia JB, Devogelaer JP, Lyritis G, Ringe JD, et al. Management of osteoporosis in the elderly. *Curr Med Res Opin.* 2008; 25(10):2373–87.
- 2 Rizzoli R. Bisphosphonates for post-menopausal osteoporosis: are they all the same? *QJM.* 2011;104(4):281–300.
- 3 Rizzoli R, Reginster JY, Boonen S, Breart G, Diez-Perez A, Felsenberg D, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. *Calcif Tissue Int.* 2011; 89(2):91–104.
- 4 Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. *J Bone Miner Res.* 2004; 19(2):278–88.
- 5 Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. *Osteoporos Int.* 2010; 21(5):723–32.
- 6 Rizzoli R, Burllet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. *Bone.* 2008; 42(5):841–7.
- 7 Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. *Ann Oncol.* 2011.
- 8 Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? *Bone.* 2009; 45(5):843–52.
- 9 Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. *Osteoporos Int.* 2011; 22(2):373–90.
- 10 Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. *J Clin Endocrinol Metab.* 2010; 95(3):1174–81.
- 11 Alendronate Summary of Product Characteristics available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000619/WC500024251.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000619/WC500024251.pdf)
12. Risedronate Summary of Product Characteristics available at: <http://www.medicines.org.uk/emc/medicine/24793/SPC/risedronate%205mg%20tablets/>
- 13 Ibandronate Summary of Product Characteristics available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000501/WC500052652.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000501/WC500052652.pdf)
- 14 Zoledronic acid Summary of Product Characteristics available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000595/WC500020940.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000595/WC500020940.pdf)